Docstoc

Healthcare, Regulatory and Reimbursement Landscape – Netherlands

Document Sample
Healthcare, Regulatory and Reimbursement Landscape – Netherlands Powered By Docstoc
					Healthcare, Regulatory and Reimbursement Landscape – Netherlands

Netherlands Embracing Generics to Counter Growing Healthcare Costs

With the elderly making up an ever greater share of the country’s population, the Netherlands is
increasingly supporting its generics sector in an attempt to address mounting healthcare costs, says a
new report from industry experts GlobalData.

The firm’s latest publication* shows that the percentage of Dutch citizens aged 65 and over has climbed
from 14.1% in 2006 to 15.6% last year, and is expected to further increase to 18.6% by the end of the
decade – unavoidably increasing the demand on the nation’s healthcare resources.

In a bid to cut the country’s healthcare deficit, the Netherlands is focusing on the use of generics as a
cost-containment tool. In 2008, health insurers introduced preference policies, which contain lists of
medicines that have the same composition (or active substance), but differ in price. This resulted from
health insurers’ preference to reimbursing these less expensive medications. Consequently, the prices of
commonly-used generic drugs fell by an average of 85% the following year.

In addition, the government allowed insurers to add biosimilar drugs in their preference policies in 2009,
providing further momentum to the country’s expanding generics market.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?CompanyID=dcstc&ID=Healthcare-
Regulatory-and-Reimbursement-Landscape-
Netherlands&ReportType=Industry_Report&title=Pharmaceuticals_and_Healthcare

Thanks in part to this system, the generic pharmaceutical market in the Netherlands increased in value
from US$832m in 2005 to an estimated US$1.8 billion in 2010, at a Compound Annual Growth Rate
(CAGR) of 15%.

With several major drugs going off-patent in the near future, GlobalData expects the Dutch generics
sector to continue its impressive expansion, providing fantastic opportunities for the country’s generics
manufacturers.

This report is an essential source of information and analysis regarding the healthcare, regulatory, and
reimbursement landscape in the Netherlands.

This report was built using data and information sourced from proprietary databases, primary and
secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients
make better, more informed decisions every day. Our research and analysis is based on the expert
knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry
insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business
intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Healthcare-Regulatory-and-Reimbursement-
Landscape-Netherlands&CompanyID=dcstc

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe:                +44 207 753 4299
                       +44 1204 543 533
Asia Pacific:          +91 40 6616 6782

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:4
posted:12/12/2012
language:
pages:2
Description: This report is an essential source of information and analysis regarding the healthcare, regulatory, and reimbursement landscape in the Netherlands.